Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025 ...

ST-503 is a zinc finger repressor, or ZFR, targeting the human gene SCN9A that encodes the Nav1.7 sodium channel. Developing small molecules that specifically target Nav1.7 is challenging due to ...

12 Three individuals had sustained fractures of the upper and lower limbs. However, unlike SCN9A and NTRK1 CIP, patients with PRDM12 mutations could experience non-global pain insensitivity. In one ...

On March 18, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced that the first patient was dosed in the Phase 2b HALT-CINP (Halneuron Treatment of Chemotherapy-Induced Neuropathic Pain ...

Sangamo Therapeutics, with a market capitalization of $211.78 million, reported its earnings for Q4 2024, posting an EPS of -0.11, slightly missing the forecast of -0.10. Revenue came in at 7.55 ...

Sangamo Therapeutics, with a market capitalization of $211.78 million, reported its earnings for Q4 2024, posting an EPS of -0.11, slightly missing the forecast of -0.10. Revenue came in at 7.55 ...

The UK's only Professor of Paediatric Bone Disease. Trained in Manchester (clinical), Cambridge (MRC and Wellcome Fellowships) and Montreal (visiting Professor at McGill). Appointed to Chair in ...